COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - NYSE:CNS - US19247A1007 - Common Stock
59.68 USD
-5.08 (-7.84%)
59.68 USD
0 (0%)
Taking everything into account, CNS scores 6 out of 10 in our fundamental rating. CNS was compared to 237 industry peers in the Capital Markets industry. CNS has an excellent profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, CNS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
CNS had a negative operating cash flow in the past year.
CNS had positive earnings in each of the past 5 years.
Each year in the past 5 years CNS had a positive operating cash flow.
1.2 Ratios
CNS has a better Return On Assets (20.48%) than 99.16% of its industry peers.
Looking at the Return On Equity, with a value of 29.83%, CNS belongs to the top of the industry, outperforming 95.78% of the companies in the same industry.
CNS has a Return On Invested Capital of 24.24%. This is amongst the best in the industry. CNS outperforms 98.31% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.11%.
The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(24.24%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROIC | 24.24% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
CNS has a better Profit Margin (29.73%) than 74.68% of its industry peers.
In the last couple of years the Profit Margin of CNS has declined.
CNS has a better Operating Margin (33.83%) than 65.40% of its industry peers.
In the last couple of years the Operating Margin of CNS has declined.
The Gross Margin of CNS (88.60%) is better than 92.83% of its industry peers.
CNS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
CNS has more shares outstanding than it did 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CNS has an Altman-Z score of 9.09. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
CNS's Altman-Z score of 9.09 is amongst the best of the industry. CNS outperforms 93.67% of its industry peers.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.09 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
CNS has a worse Current ratio (0.79) than 65.40% of its industry peers.
CNS has a Quick Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.79, CNS is doing worse than 64.98% of the companies in the same industry.
CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.87% over the past year.
The Earnings Per Share has been growing slightly by 2.50% on average over the past years.
Looking at the last year, CNS shows a quite strong growth in Revenue. The Revenue has grown by 11.13% in the last year.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
CNS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.
CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.21% yearly.
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.44 indicates a rather expensive valuation of CNS.
Compared to the rest of the industry, the Price/Earnings ratio of CNS is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 25.56, CNS is valued a bit cheaper.
CNS is valuated rather expensively with a Price/Forward Earnings ratio of 17.23.
CNS's Price/Forward Earnings ratio is in line with the industry average.
CNS is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.62, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.44 | ||
| Fwd PE | 17.23 |
4.2 Price Multiples
77.64% of the companies in the same industry are more expensive than CNS, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.16 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)4.26
PEG (5Y)7.78
EPS Next 2Y8.74%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.79%. Purely for dividend investing, there may be better candidates out there.
In the last 3 months the price of CNS has falen by -21.75%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
CNS's Dividend Yield is comparable with the industry average which is at 8.48.
Compared to an average S&P500 Dividend Yield of 2.44, CNS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.79% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
76.25% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
59.68
-5.08 (-7.84%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners60.28%
Inst Owner Change-6.01%
Ins Owners22.51%
Ins Owner Change0.49%
Market Cap3.04B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target81.26 (36.16%)
Short Float %6.4%
Short Ratio6.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.79% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.14%
PT rev (3m)1.27%
EPS NQ rev (1m)2.48%
EPS NQ rev (3m)2.48%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)1.85%
Revenue NQ rev (3m)2.85%
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)0.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.44 | ||
| Fwd PE | 17.23 | ||
| P/S | 5.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.53 | ||
| P/tB | 5.74 | ||
| EV/EBITDA | 16.16 |
EPS(TTM)3.07
EY5.14%
EPS(NY)3.46
Fwd EY5.8%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.83
BVpS10.79
TBVpS10.4
PEG (NY)4.26
PEG (5Y)7.78
Graham Number27.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROCE | 31.59% | ||
| ROIC | 24.24% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 32.58% | ||
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 9.09 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year17.56%
EBIT Next 3Y18.41%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%
COHEN & STEERS INC / CNS FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CNS.
Can you provide the valuation status for COHEN & STEERS INC?
ChartMill assigns a valuation rating of 3 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
Can you provide the profitability details for COHEN & STEERS INC?
COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.
What are the PE and PB ratios of COHEN & STEERS INC (CNS) stock?
The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 19.44 and the Price/Book (PB) ratio is 5.53.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.